2-methoxy-N-(thiophen-2-ylmethylene)ethanamine | 105387-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-methoxy-N-(thiophen-2-ylmethylene)ethanamine
• 英文别名: N-(2-methoxyethyl)-1-thiophen-2-ylmethanimine
• CAS: 105387-30-2
• 化学式: C₈H₁₁NOS
• 分子量: 169.247
• InChiKey: ZIPKMYGIICUWEP-UHFFFAOYSA-N

物化性质

• 沸点：
  245.3±20.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-N-(thiophen-2-ylmethylene)ethanamine 在 溶剂黄146 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 32.0h， 生成 N-(3-cyanophenyl)-2-(2-methoxyethyl)-1-oxo-3-(thiophen-2-yl)-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
  参考文献：
  名称：

  Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides

  摘要：

  Phenotypic whole-cell screening in erythrocytic cocultures of Plasmodium falciparum identified a series of dihydroisoquinolones that possessed potent antimalarial activity against multiple resistant strains of P. falciparum in vitro and show no cytotoxicity to mammalian cells. Systematic structure activity studies revealed relationships between potency and modifications at N-2, C-3, and C-4. Careful structure property relationship studies, coupled with studies of metabolism, addressed the poor aqueous solubility and metabolic vulnerability, as well as potential toxicological effects, inherent in the more potent primary screening hits such as 10b. Analogues 13h and 13i, with structural modifications at each site, were shown to possess excellent antimalarial activity in vivo. The (+)-(35,4S) enantiomer of 13i and similar analogues were identified as the more potent. On the basis of these studies, we have selected (+)-13i for further study as a preclinical candidate.

  DOI：

  10.1021/acs.jmedchem.6b00752
• 作为产物：
  描述：

  2-噻吩甲醛 、 2-甲氧基乙胺 反应 6.0h， 以100%的产率得到2-methoxy-N-(thiophen-2-ylmethylene)ethanamine
  参考文献：
  名称：

  [EN] ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION
  [FR] NOUVEAUX INHIBITEURS DE LA RÉPLICATION DE FLAVIVIRUS

  摘要：

  公开号：

  WO2010055164A3

文献信息

• NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION
  申请人：Bardiot Dorothée

  公开号：US20110224208A1

  公开（公告）日：2011-09-15

  The present invention relates to a series of Isoquinolone derivatives which are suitable to treat infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Hepatitis C virus (HCV). The present invention also relates to Isoquinolone compounds for use as a medicine for the prevention or treatment of viral infections, preferably infections with viruses belonging to the family of the Flaviviridae.

  本发明涉及一系列异喹啉衍生物，适用于治疗属于黄病毒科家族的病毒感染，更优选地是治疗丙型肝炎病毒（HCV）感染。本发明还涉及异喹啉化合物作为预防或治疗病毒感染的药物，优选是治疗属于黄病毒科家族的病毒感染。
• [EN] ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS DE LA RÉPLICATION DE FLAVIVIRUS
  申请人：UNIV LEUVEN KATH

  公开号：WO2010055164A3

  公开（公告）日：2010-07-08
• Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides
  作者：David M. Floyd、Philip Stein、Zheng Wang、Jian Liu、Steve Castro、Julie A. Clark、Michele Connelly、Fangyi Zhu、Gloria Holbrook、Amy Matheny、Martina S. Sigal、Jaeki Min、Rajkumar Dhinakaran、Senthil Krishnan、Sridevi Bashyum、Spencer Knapp、R. Kiplin Guy

  DOI：10.1021/acs.jmedchem.6b00752

  日期：2016.9.8

  Phenotypic whole-cell screening in erythrocytic cocultures of Plasmodium falciparum identified a series of dihydroisoquinolones that possessed potent antimalarial activity against multiple resistant strains of P. falciparum in vitro and show no cytotoxicity to mammalian cells. Systematic structure activity studies revealed relationships between potency and modifications at N-2, C-3, and C-4. Careful structure property relationship studies, coupled with studies of metabolism, addressed the poor aqueous solubility and metabolic vulnerability, as well as potential toxicological effects, inherent in the more potent primary screening hits such as 10b. Analogues 13h and 13i, with structural modifications at each site, were shown to possess excellent antimalarial activity in vivo. The (+)-(35,4S) enantiomer of 13i and similar analogues were identified as the more potent. On the basis of these studies, we have selected (+)-13i for further study as a preclinical candidate.